ProShares Ultra NASDAQ Biotechnology
BIB
BIB
24 hedge funds and large institutions have $11.6M invested in ProShares Ultra NASDAQ Biotechnology in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Holders
24
Holding in Top 10
–
Calls
$2.54M
Puts
$2.24M
Top Buyers
| 1 | +$2.4M | |
| 2 | +$1.24M | |
| 3 | +$878K | |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$627K |
| 5 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
+$271K |
Top Sellers
| 1 | -$483K | |
| 2 | -$427K | |
| 3 | -$422K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$163K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$84K |